April 18, 2025

Mirco Friedrich: Forbes-List “30 Under 30 Europe”

Mirco Friedrich: Forbes-List “30 Under 30 Europe”
Go back

Mirco Julian Friedrich from the DKFZ, HI-STEM* and Heidelberg University Hospital (UKHD) was included in the renowned Forbes ‘30 Under 30 Europe’ list in the Science & Healthcare category.

The physician and cancer researcher, who has headed the Haematology and Immune Engineering junior research group since this year, initially developed successful approaches to reactivate the immune system against brain tumours.

With his current research, Friedrich aims to develop innovative strategies to reprogramme the human immune system by integrating synthetic immunology, genome editing and AI-controlled bioengineering. The aim is to prevent cancer, strengthen immune resilience and promote healthy ageing.

With this award, the US business magazine Forbes annually recognises outstanding young personalities under the age of 30 who stand out in their fields through their innovative strength, social relevance and exceptional achievements.


*The Heidelberg Institute for Stem Cell Research and Experimental Medicine (HI-STEM) gGmbH was founded in 2008 as a public-private partnership between the DKFZ and the Dietmar Hopp Foundation.

Our latest News

discover more
Tailor-Made Fertilization

Tailor-Made Fertilization

Excessive fertilization in agriculture weakens crops, threatens drinking water quality, and harms the soil. Researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB are now developing an alternative fertilizer that is fully biodegradable, supplies plants exclusively with the nutrients they need, and prevents over-fertilization. More information in German below: Jahr für Jahr werden […]

read more
Two German Cancer Awards for Researchers at Heidelberg University’s Faculty of Medicine

Two German Cancer Awards for Researchers at Heidelberg University’s Faculty of Medicine

Professor Dr. Jessica Hassel, Faculty of Medicine Heidelberg at Heidelberg University and Head of the Skin Cancer Center at Heidelberg University Hospital and the National Center for Tumor Diseases (NCT) Heidelberg, has been awarded in the category “Clinical Research.” Professor Dr. Dr. Felix Sahm, also from the Faculty of Medicine Heidelberg, Department of Neuropathology at […]

read more
Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at least 40 kg. The medicine is to […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp